OLMA · Olema Pharmaceuticals, Inc.
$10.22
-4.40% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-4.0
Dividend yield
—
Beta
1.99
Avg volume
1M
Employees
0K
Daily Change %
-4.40%
5 Days Change
-3.63%
10 Days Change
-0.67%
30 Days Change
-0.67%
60 Days Change
-13.01%
Month to Day Change
-1.89%
Year to Day Change
-58.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OLMA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
JP Morgan
Overweight$46.00
+330.3% vs priceCitigroup
Buy$59.00
+451.9% vs priceGoldman Sachs
Buy$27.00
+152.6% vs priceUBS
Buy$45.00
+321.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | JP Morgan | Maintains | Overweight | $52.00 → $46.00 |
| 2026-08-11 | Citigroup | Maintains | Buy | $62.00 → $59.00 |
| 2026-08-11 | HC Wainwright & Co. | Maintains | Buy | $38.00 → $36.00 |
| 2026-05-13 | Guggenheim | Maintains | Buy | $38.00 → $35.00 |
| 2026-03-27 | Wolfe Research | Initiates | Peer Perform | $0.00 |
| 2026-03-18 | JP Morgan | Maintains | Overweight | $55.00 → $58.00 |
| 2026-03-18 | Goldman Sachs | Maintains | Buy | $38.00 → $27.00 |
| 2026-03-17 | Citigroup | Maintains | Buy | $60.00 → $62.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.4% below the 50-day MA ($11.28).
- Price vs 200-day MA: Trading 41.7% below the 200-day MA ($17.53).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.00) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($7.75) and high ($35.83).
OLMA Price Chart
Loading chart for OLMA…
Fundamentals
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.